[Preventive effect of ticlopidine on peplomycin pulmonary fibrosis].
A comparative clinical study examined the preventive effect of ticlopidine hydrochloride (hereinafter referred to as ticlopidine, anti-platelet drug) on Peplomycin sulfate (hereinafter referred to as Peplomycin) pulmonary fibrosis. In clinical evaluation, pulmonary function (PaO2, DLco) and biological fibrosis markers (angiotensin I converting enzyme, type III procollagen peptide, phospholipid) were measured. PaO2 and DLco using ticlopidine showed improvement, but statistical significance was not observed. Changes in biological fibrosis markers due to Peplomycin administration were observed in accordance with earlier experiments. Importantly however, the variance of type III procollagen peptide in the ticlopidine group was significantly suppressed (p less than 0.10). As a result, ticlopidine has the potential to prevent Peplomycin pulmonary side effects during clinical use.
Department of Urology, Saitama Cancer Center.
K
K
Tari
T
T
Tsujii
J
J
Yonese
T
T
Saito
F
F
Oowada
H
H
Fukuda
T
T
Negishi
T
T
Yamada
H
H
Saito
K
K
Yoshida
D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007260:Infusion Pumps; D017663:Peplomycin; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000517:prevention & control; D013988:Ticlopidine / Q000627:therapeutic use*; D014571:Urologic Neoplasms / Q000188:drug therapy*
D001761:Bleomycin; D017663:Peplomycin; D013988:Ticlopidine